Related references
Note: Only part of the references are listed.Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers
Arne Gessner et al.
CARDIOVASCULAR DIABETOLOGY (2022)
Correlation of physical and cognitive impairment in diabetic and hypertensive frail older adults
Pasquale Mone et al.
CARDIOVASCULAR DIABETOLOGY (2022)
13. Older Adults: Standards of Medical Care in Diabetes-2022
DIABETES CARE (2022)
Heart failure with preserved, mid-range, and reduced ejection fraction across health care settings: an observational study
Annemarijn R. de Boer et al.
ESC HEART FAILURE (2022)
Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease A Meta-analysis
Mukul Bhattarai et al.
JAMA NETWORK OPEN (2022)
Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies
Kazunori Omote et al.
ANNUAL REVIEW OF MEDICINE (2022)
Cognitive dysfunction correlates with physical impairment in frail patients with acute myocardial infarction
Pasquale Mone et al.
AGING CLINICAL AND EXPERIMENTAL RESEARCH (2022)
Heart failure in diabetes
Stanislovas S. Jankauskas et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2021)
Neuroprotective Effect of SGLT2 Inhibitors
Agnieszka Pawlos et al.
MOLECULES (2021)
Cardiovascular Endocrinology: Evolving Concepts and Updated Epidemiology of Relevant Diseases
Fahimeh Varzideh et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Patients With Type 2 Diabetes Mellitus and Heart Failure Benefit More From Sodium-Glucose Cotransporter 2 Inhibitor: A Systematic Review and Meta-Analysis
Chengcong Chen et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
SGLT2 inhibitors in cardiovascular medicine
Fahimeh Varzideh et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2021)
Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin
Atsushi Tanaka et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Stefan D. Anker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Cognitive Impairment in Frail Hypertensive Elderly Patients: Role of Hyperglycemia
Pasquale Mone et al.
CELLS (2021)
Sodium-glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review
Roy Rasalam et al.
ESC HEART FAILURE (2021)
The degree of frailty as a translational measure of health in aging
Susan E. E. Howlett et al.
NATURE AGING (2021)
Combinations of cardiac and non-cardiac predictors for prognoses in patients with acute heart failure
Daihiko Hakuno et al.
EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES (2021)
Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes
Carmen Hierro-Bujalance et al.
ALZHEIMERS RESEARCH & THERAPY (2020)
Cost-effectiveness of Interventions to Manage Diabetes: Has the Evidence Changed Since 2008?
Karen R. Siegel et al.
DIABETES CARE (2020)
SGLT2i: beyond the glucose-lowering effect
Lihua Ni et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality Insights From the EMPA-REG OUTCOME Trial
Gianluigi Savarese et al.
CIRCULATION (2019)
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
Helena W. Rodbard et al.
DIABETES CARE (2019)
Physical Function, Frailty, Cognition, Depression, and Quality of Life in Hospitalized Adults >= 60 Years With Acute Decompensated Heart Failure With Preserved Versus Reduced Ejection Fraction
Haider J. Warraich et al.
CIRCULATION-HEART FAILURE (2018)
The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
Sebastian Steven et al.
REDOX BIOLOGY (2017)
Metformin-associated lactic acidosis: Current perspectives on causes and risk
Ralph DeFronzo et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease
Jie Hong et al.
DIABETES CARE (2013)
SGLT inhibitors in management of diabetes
Abd A. Tahrani et al.
LANCET DIABETES & ENDOCRINOLOGY (2013)
Frailty in older adults: Evidence for a phenotype
LP Fried et al.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES (2001)